Skip to main content

Featured

Wall St Futures Slip as Geopolitical Uncertainty and Mixed Earnings Weigh on Sentiment

Wall Street futures slipped early Thursday as investors grew cautious in the absence of clear signals on the U.S.–Iran war, while a wave of mixed earnings added to the uncertainty. Iran’s seizure of two ships in the Strait of Hormuz and its demand that the U.S. lift its naval blockade have heightened geopolitical tensions, even after President Donald Trump extended the ceasefire indefinitely. The standoff continues to keep oil prices above $100 per barrel , raising concerns about a potential inflation flare‑up.  Economists warn that even if the conflict eases, the global economy may take time to normalize after one of the largest oil supply disruptions in decades.  As of early morning trading, Dow E‑minis were down 0.73%, S&P 500 E‑minis slipped 0.50%, and Nasdaq 100 E‑minis fell 0.48% , reflecting a broader pullback in risk appetite.  Earnings added another layer of volatility. Tesla shares fell after the company boosted its annual spending plan to more than $25...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment